The market is a fickle place at times. All the strong believers (myself included) knew that the data was incredible from the CHF Trial. The shorters and sellers somehow missed the magic of the initial report. Next up will be partnership $$$ and approval through FDA. A huge addressable market and this will put mesoblast on the map.
Ann: Rexlemestrocel Reduces Heart Attacks/Strokes/CV Death in CHF, page-62
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.57 |
Change
-0.210(11.8%) |
Mkt cap ! $1.792B | |||
| Open | High | Low | Value | Volume |
| $1.72 | $1.74 | $1.52 | $15.63M | 9.716M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 5127 | $1.57 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.57 | 39613 | 3 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |